Raul Pellini1, Aldo Venuti2, Fulvia Pimpinelli3, Elva Abril3, Giovanni Blandino4, Flaminia Campo1, Laura Conti5, Armando De Virgilio6, Federico De Marco7, Enea Gino Di Domenico3, Ornella Di Bella8, Simona Di Martino9, Fabrizio Ensoli3, Diana Giannarelli10, Chiara Mandoj5, Valentina Manciocco1, Paolo Marchesi1, Francesco Mazzola1, Silvia Moretto1, Gerardo Petruzzi1, Fabrizio Petrone11, Barbara Pichi1, Martina Pontone3, Jacopo Zocchi1, Antonello Vidiri12, Branka Vujovic8, Giulia Piaggio13, Aldo Morrone14, Gennaro Ciliberto15. 1. Department Otolaryngology Head and Neck Surgery, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy. 2. HPV Unit, UOSD Tumor Immunology and Immunotherapy, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy. 3. Department of Microbiology and Virology, IRCCS San Gallicano Dermatological Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy. 4. Oncogenomic and Epigenetic Unit, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy. 5. Department Clinical Pathology and Cancer Biobank, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy. 6. Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20089 Milan, Italy. 7. Department of RiDAIT, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy. 8. Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy. 9. Department of Pathology, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy. 10. Biostatistical Unit, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy. 11. U.O.C. D.I.T.R.A.R. IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy. 12. Department of Radiology and Diagnostic Imaging, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy. 13. UOSD SAFU, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy. 14. Scientific Direction, IRCCS San Gallicano Dermatological Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy. 15. Scientific Direction, IRCCS Regina Elena National Cancer Institute, Istituti Fisioterapici Ospitalieri (IFO), 00144 Rome, Italy.
Abstract
BACKGROUND: The first goal of the study was to analyse the antibody titre 21 days after the first dose of the BNT162b2 vaccine in a group of 252 healthcare workers (HCW). The second goal was to analyse how the antibody titre changes in correlation with age, gender and body mass index (BMI). METHODS: Participants had a nasopharyngeal swab for SARS-CoV-2 and were assessed for the presence of SARS-CoV-2 antibodies at baseline and 21 days after the BNT162b2 priming dose. RESULTS: First dose of BNT162b2 activated immune responses in 98% of the participants. Five HWC had no increase in antibody titre 21 days after the first dose. Antibody titre was greater in young (<38 years) vs. older participants (<38 vs. 47-56 p = 0.002; <38 vs. >56 p = 0.001). Higher antibody levels were detected in underweight vs. pre-obesity group (p = 0.026) and in normal-weight vs. pre-obesity group (p = 0.007). This association was confirmed after adjusting for age (p = 0.0001) and gender (p = 0.00001). CONCLUSIONS: Our study demonstrates that a single dose of BNT162b2 activates the immune response, and being young and normal-weight correlate positively with this response. Larger specifically designed clinical trials are needed to validate these results.
BACKGROUND: The first goal of the study was to analyse the antibody titre 21 days after the first dose of the BNT162b2 vaccine in a group of 252 healthcare workers (HCW). The second goal was to analyse how the antibody titre changes in correlation with age, gender and body mass index (BMI). METHODS:Participants had a nasopharyngeal swab for SARS-CoV-2 and were assessed for the presence of SARS-CoV-2 antibodies at baseline and 21 days after the BNT162b2 priming dose. RESULTS: First dose of BNT162b2 activated immune responses in 98% of the participants. Five HWC had no increase in antibody titre 21 days after the first dose. Antibody titre was greater in young (<38 years) vs. older participants (<38 vs. 47-56 p = 0.002; <38 vs. >56 p = 0.001). Higher antibody levels were detected in underweight vs. pre-obesity group (p = 0.026) and in normal-weight vs. pre-obesity group (p = 0.007). This association was confirmed after adjusting for age (p = 0.0001) and gender (p = 0.00001). CONCLUSIONS: Our study demonstrates that a single dose of BNT162b2 activates the immune response, and being young and normal-weight correlate positively with this response. Larger specifically designed clinical trials are needed to validate these results.
Authors: M H García-Hernández; E Rodríguez-Varela; R E García-Jacobo; M Hernández-De la Torre; E E Uresti-Rivera; R González-Amaro; D P Portales-Pérez Journal: Obes Res Clin Pract Date: 2018-08-13 Impact factor: 2.288
Authors: Anatoly V Rubtsov; Kira Rubtsova; Aryeh Fischer; Richard T Meehan; Joann Z Gillis; John W Kappler; Philippa Marrack Journal: Blood Date: 2011-05-04 Impact factor: 22.113
Authors: Jason DeFuria; Anna C Belkina; Madhumita Jagannathan-Bogdan; Jennifer Snyder-Cappione; Jordan David Carr; Yanina R Nersesova; Douglas Markham; Katherine J Strissel; Amanda A Watkins; Min Zhu; Jessica Allen; Jacqueline Bouchard; Gianluca Toraldo; Ravi Jasuja; Martin S Obin; Marie E McDonnell; Caroline Apovian; Gerald V Denis; Barbara S Nikolajczyk Journal: Proc Natl Acad Sci U S A Date: 2013-03-11 Impact factor: 11.205
Authors: Gerardo Petruzzi; Armando De Virgilio; Barbara Pichi; Francesco Mazzola; Jacopo Zocchi; Giuseppe Mercante; Giuseppe Spriano; Raul Pellini Journal: Head Neck Date: 2020-04-30 Impact factor: 3.147
Authors: Abishek Chandrashekar; Jinyan Liu; Amanda J Martinot; Katherine McMahan; Noe B Mercado; Lauren Peter; Lisa H Tostanoski; Jingyou Yu; Zoltan Maliga; Michael Nekorchuk; Kathleen Busman-Sahay; Margaret Terry; Linda M Wrijil; Sarah Ducat; David R Martinez; Caroline Atyeo; Stephanie Fischinger; John S Burke; Matthew D Slein; Laurent Pessaint; Alex Van Ry; Jack Greenhouse; Tammy Taylor; Kelvin Blade; Anthony Cook; Brad Finneyfrock; Renita Brown; Elyse Teow; Jason Velasco; Roland Zahn; Frank Wegmann; Peter Abbink; Esther A Bondzie; Gabriel Dagotto; Makda S Gebre; Xuan He; Catherine Jacob-Dolan; Nicole Kordana; Zhenfeng Li; Michelle A Lifton; Shant H Mahrokhian; Lori F Maxfield; Ramya Nityanandam; Joseph P Nkolola; Aaron G Schmidt; Andrew D Miller; Ralph S Baric; Galit Alter; Peter K Sorger; Jacob D Estes; Hanne Andersen; Mark G Lewis; Dan H Barouch Journal: Science Date: 2020-05-20 Impact factor: 47.728
Authors: Sang Won Lee; Ji-Yong Moon; Sun-Kyung Lee; Hyun Lee; SeolHwa Moon; Sung Jun Chung; Yoomi Yeo; Tai Sun Park; Dong Won Park; Tae-Hyung Kim; Jang Won Sohn; Ho Joo Yoon; Sang-Heon Kim Journal: Front Immunol Date: 2021-11-25 Impact factor: 7.561
Authors: Brian A Chu; Vijaya Surampudi; Zhaoping Li; Christina Harris; Teresa Seeman; Keith C Norris; Tara Vijayan Journal: Int J Environ Res Public Health Date: 2022-01-20 Impact factor: 3.390